MedWatch

Analyst: New study confirms that Eli Lilly's tirzepatide is a good product

Eli Lilly has published strong results for its study of the diabetes treatment tirzepatide, which took up the last piece of the puzzle needed for an FDA application, Sydbank analyst Søren Løntoft Hansen says.

Photo: Sydbank/PR

On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.

These results were strong, says Sydbank Chief Equity Analyst Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs